TY - JOUR
T1 - Randomized controlled trial validating the use of perispinal etanercept to reduce post-stroke disability has wide-ranging implications
AU - Clark, Ian A.
N1 - Publisher Copyright:
© 2020, © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/3/3
Y1 - 2020/3/3
N2 - Developing effective drug treatments for neurodegenerative disorders has always been hamstrung by the accepted inability of large molecules (roughly those with a molecular weight greater than 600 Daltons) to cross the blood-brain barrier (BBB) in therapeutic quantities when administered systemically. The dogma has been that a simple, noninvasive way to accomplish this goal is not possible with many agents, including biologicals, because they are too large. Various novel technologies to breach the BBB have been attempted, but with little success. A randomized double-blind, placebo-controlled clinical trial (RCT) administering a widely used anti-tumor necrosis factor (TNF) biological, etanercept, given via perispinal injection, which bypasses the BBB, turns this dogma on its head. This new trial holds much promise for stroke survivors, as well as having implications for developing treatments based on other large molecules for this and other brain disorders.
AB - Developing effective drug treatments for neurodegenerative disorders has always been hamstrung by the accepted inability of large molecules (roughly those with a molecular weight greater than 600 Daltons) to cross the blood-brain barrier (BBB) in therapeutic quantities when administered systemically. The dogma has been that a simple, noninvasive way to accomplish this goal is not possible with many agents, including biologicals, because they are too large. Various novel technologies to breach the BBB have been attempted, but with little success. A randomized double-blind, placebo-controlled clinical trial (RCT) administering a widely used anti-tumor necrosis factor (TNF) biological, etanercept, given via perispinal injection, which bypasses the BBB, turns this dogma on its head. This new trial holds much promise for stroke survivors, as well as having implications for developing treatments based on other large molecules for this and other brain disorders.
KW - Blood-brain barrier
KW - TNF
KW - double-blind controlled trial
KW - etanercept
KW - perispinal route of administration
KW - post-stroke therapy
UR - http://www.scopus.com/inward/record.url?scp=85079393509&partnerID=8YFLogxK
U2 - 10.1080/14737175.2020.1727742
DO - 10.1080/14737175.2020.1727742
M3 - Article
SN - 1473-7175
VL - 20
SP - 203
EP - 205
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
IS - 3
ER -